Randomized, Double-blind, Placebo-controlled Phase II Study to Examine the Effects of DAS181 in Immunocompromised Patients With Parainfluenza Infection (DAS181-2-05)
This study has been withdrawn prior to enrollment.
Sponsor:
Ansun Biopharma, Inc.
Information provided by (Responsible Party):
Ansun Biopharma, Inc.
ClinicalTrials.gov Identifier:
NCT01644877
First received: July 17, 2012
Last updated: July 24, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Study Status: | This study has been withdrawn prior to enrollment. |
|---|---|
| Estimated Study Completion Date: | October 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |